A randomized clinical trial has produced a surprising finding about cannabis and the heart: habitual users experienced approximately 9% fewer premature heartbeats on days when they inhaled cannabis than on days when they abstained. The result challenges expectations shaped by earlier observational research, which has frequently linked cannabis exposure with an increased heart rate and possible cardiovascular risk. Researchers at the University of California, San Francisco, emphasized that the study does not show cannabis to be beneficial for the heart, nor does it provide a basis for changing medical or recreational behavior. Instead, they say the findings offer an unexpected clue about the biological mechanisms that generate abnormal heart rhythms.
The study, published August 12 in the Journal of the American College of Cardiology, is among the first investigations to examine the short-term cardiovascular effects of inhaled cannabis while people go about their ordinary lives. Rather than relying on participants to recall symptoms or on medical records to identify arrhythmias, the investigators continuously recorded every heartbeat. The approach allowed them to compare cardiac activity during cannabis-use and abstinence days in the same individuals, reducing the influence of differences in age, health, lifestyle, and underlying physiology between separate groups.
The trial included 108 adults who regularly smoked or vaped cannabis and had no history of clinically diagnosed cardiac arrhythmias. For 14 days, participants were randomly assigned each day either to inhale cannabis or to abstain. They wore continuously recording electrocardiographic monitors, which detect the timing and electrical pattern of each heartbeat, along with activity trackers, sleep monitors, and continuous glucose monitors. Because the study used a randomized crossover design, each participant served as their own control. This enabled researchers to examine whether cardiac patterns changed during cannabis exposure relative to periods without inhalation, under conditions that more closely resembled daily life than a laboratory experiment.
The main difference involved cardiac ectopy, a term describing extra or early heartbeats that interrupt the heart’s normal rhythm. Cannabis inhalation was associated with a statistically significant reduction in these events, and the decrease was driven primarily by fewer premature atrial contractions, or PACs. PACs originate in the atria, the heart’s upper chambers, before the normal electrical signal from the sinoatrial node—the heart’s natural pacemaker—can trigger a regular beat. Although PACs are common and often harmless in isolation, frequent episodes can indicate electrical instability in the atria and are considered the strongest known predictor of future atrial fibrillation, an irregular rhythm that can impair cardiac function and increase the risk of stroke.
The result is especially notable because cannabis is widely known to produce acute changes in cardiovascular physiology. Tetrahydrocannabinol, or THC, the principal psychoactive compound in cannabis, can activate cannabinoid receptors in the nervous system and cardiovascular tissues. This may influence autonomic balance, the competing effects of the sympathetic and parasympathetic nervous systems that regulate heart rate, blood pressure, and electrical conduction. Cannabis exposure has also been associated in other settings with faster heart rates, changes in blood pressure, and altered vascular tone. Those effects led investigators to anticipate that inhalation might increase premature heartbeats rather than reduce them.
No statistically significant change was detected in premature ventricular contractions, or PVCs, which originate in the heart’s lower chambers, the ventricles. PVCs are also common, but a high burden can be associated with structural heart disease and may help predict the development of heart failure. The contrast between the reduction in PACs and the absence of a measurable effect on PVCs suggests that cannabis inhalation may influence specific parts of the heart’s electrical system rather than producing a uniform effect on cardiac excitability. The finding does not establish a protective mechanism, but it may help researchers distinguish the pathways involved in atrial and ventricular ectopy.
The investigators also found no significant differences between cannabis-use and abstinence days in participants’ daily step counts, sleep duration, or glucose levels. These measurements were included because cannabis might indirectly affect cardiac rhythm by changing physical activity, sleep, metabolism, or blood sugar. The absence of detectable changes in those factors suggests that the reduction in PACs was not obviously explained by participants moving less, sleeping longer, or experiencing altered glucose regulation during cannabis-use days. However, the study was designed to examine acute effects and cannot determine whether the observed rhythm differences persist over weeks or years.
Gregory Marcus, a cardiologist and atrial fibrillation researcher at UCSF, said the findings contradicted the investigators’ original hypothesis and illustrated why randomized trials are essential. Observational studies can identify associations, but they are vulnerable to confounding factors: people who use cannabis may differ from nonusers in stress levels, tobacco exposure, alcohol consumption, diet, medical conditions, or access to care. Even when statistical methods attempt to account for these differences, they cannot fully establish causation. Randomized assignment of daily exposure and abstinence provides stronger evidence that the intervention itself contributed to the short-term change, although the present trial cannot eliminate every source of uncertainty.
Several limitations remain important. The participants were habitual cannabis users, so the results may not apply to people who rarely use cannabis or to those who have cardiovascular disease, atrial fibrillation, heart failure, or other diagnosed arrhythmias. The study examined inhaled cannabis rather than edible products, tinctures, or other formulations, each of which can produce different absorption patterns and durations of effect. The investigators also evaluated relatively short-term exposure and did not establish which cannabinoid, dose, inhalation method, or blood concentration was responsible for the change in PAC frequency. Most importantly, fewer premature atrial contractions do not automatically translate into fewer heart attacks, strokes, cases of atrial fibrillation, or deaths.
The authors therefore caution against interpreting the findings as evidence that cannabis improves cardiovascular health. The overall consequences of inhaled cannabis could still be harmful, particularly because smoke and vapor may expose the lungs and circulation to irritants and other compounds, while THC can cause acute changes in heart rate and blood pressure. Instead, the researchers view the unexpected decrease in PACs as a physiological lead that may reveal how premature atrial contractions arise. If future studies identify the specific molecular or autonomic pathway involved, that mechanism could eventually inspire safer treatments for abnormal heart rhythms without relying on cannabis exposure. Larger trials involving diverse participants, standardized doses, longer follow-up, and direct assessment of clinical outcomes will be needed before the finding can be placed in a broader medical context.
Subject of Research: People
Article Title: Acute Effects of Cannabis Inhalation on Cardiac Ectopy, Physical Activity, Sleep, and Glucose
News Publication Date: 12-Aug-2026
Web References: https://www.jacc.org/doi/10.1016/j.jacc.2026.07.014; https://www.ucsf.edu/
References: Journal of the American College of Cardiology. DOI: 10.1016/j.jacc.2026.07.014
Keywords: Cannabis, cardiac ectopy, premature atrial contractions, premature ventricular contractions, atrial fibrillation, cardiac arrhythmias, cardiology, randomized clinical trial, electrocardiography, cardiovascular health
